ArticleMedical oncology (Northwood, London, England)2025
Calendula officinalis as a source of KRAS-targeted anticancer agents: a comprehensive computational assessment.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionKRAS mutations are among the most potent oncogenic drivers in several highly aggressive cancers, including pancreatic, colorectal, and non-small cell lung cancer (NSCLC), and are typically associated with poor clinical outcomes and resistance to conventional therapies. Mutant KRAS proteins, particularly those with alterations at codons 12, 13, and 61, remain challenging therapeutic targets due to their constitutive activation and disruption of key signaling pathways.
methodsA combined computational pipeline was employed to identify promising inhibitors. Selected phytochemicals from Calendula officinalis were screened for drug-likeness using Lipinski's Rule of Five and evaluated for their ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties. Docking protocol validation was performed by redocking co-crystallized ligands into their original binding sites, yielding RMSD values ≤ 2.0 Å, which confirmed the reliability of the docking approach. Binding interactions with KRAS mutants were analyzed using molecular docking via AutoDock Vina. To enhance accuracy, structural data from the Protein Data Bank (PDB) were incorporated. Promising candidates were further examined through molecular dynamics simulations and MM-GBSA analysis to estimate their binding free energies.
resultsThe computational analysis revealed several C. officinalis compounds with strong binding affinities toward key KRAS mutants, particularly G12C, G13D, and G12V. All top compounds complied with ADMET, exhibited no predicted mutagenicity or hepatotoxicity, and showed low predicted acute toxicity. These compounds demonstrated favorable drug-likeness and ADMET profiles, supporting their potential as viable lead structures. DISCUSSION /
conclusionsDespite the historical challenges in targeting KRAS-mutant proteins, the findings of this study support the potential of natural products as scaffolds for anticancer drug discovery as a source for developing novel anticancer therapies. The identified phytochemicals from C. officinalis such as calendasaponin D and procyanidin A2 may serve as potential leads for future preclinical and experimental validation against KRAS-driven malignancies.
Indexed as
Identifiers
41320730What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.